studyId: syn51133946 studyName: DHART SPORE Project 3 Phase 1 - A High Content Clinical Trial of the MEK Inhibitor Trametinib in Juvenile Myelomonocytic Leukemia (JMML) initiative: Developmental and HyperActive Ras Tumor Specialized Programs of Research Excellence fundingAgency: NIH-NCI